Search

Your search keyword '"Mycobacterium smegmatis drug effects"' showing total 774 results

Search Constraints

Start Over You searched for: Descriptor "Mycobacterium smegmatis drug effects" Remove constraint Descriptor: "Mycobacterium smegmatis drug effects"
774 results on '"Mycobacterium smegmatis drug effects"'

Search Results

1. Genetic stability of Mycobacterium smegmatis under the stress of first-line antitubercular agents.

2. Inhibition mechanism of potential antituberculosis compound lansoprazole sulfide.

3. Overexpression of outer membrane protein A (OmpA) increases aminoglycoside sensitivity in mycobacteria.

4. Lighting up Mycobacteria with membrane-targeting peptides.

5. 5'-Methoxyarmillane, a Bioactive Sesquiterpenoid Aryl Ester from the Fungus Armillaria ostoyae.

6. Ajoene: a natural compound with enhanced antimycobacterial and antibiofilm properties mediated by efflux pump modulation and ROS generation against M. Smegmatis.

7. Disrupting Mycobacterium smegmatis biofilm using enzyme-immobilized rifampicin loaded silk fibroin nanoparticles for dual anti-bacterial and anti-biofilm action.

8. The CRISPR-dCas9 interference system suppresses inhA gene expression in Mycobacterium smegmatis.

9. Use of stable isotope combined with intact cell lipidomic by routine MALDI mass spectrometry analysis for rapid drug susceptibility assay in mycobacteria.

10. Biochemical characterization of Mycobacterial RNA polymerases.

11. Elucidating the molecular properties and anti-mycobacterial activity of cysteine peptidase domain of D29 mycobacteriophage endolysin.

12. Deciphering the possible role of MmpL7 efflux pump in SQ109 resistance in Mycobacterium tuberculosis.

13. Cryo-EM structures reveal the molecular mechanism of HflX-mediated erythromycin resistance in mycobacteria.

14. The rv2820c K114N mutation is related with capreomycin tolerance.

15. Intracellular peroxynitrite perturbs redox balance, bioenergetics, and Fe-S cluster homeostasis in Mycobacterium tuberculosis.

16. Mycobacterium smegmatis MfpC is a GEF that regulates mfpA translationally to alter the fluoroquinolone efficacy.

17. Structure and in vivo psoralen DNA crosslink repair activity of mycobacterial Nei2.

18. Conserved Evolutionary Trajectory Can Be Perturbed to Prevent Resistance Evolution under Norfloxacin Pressure by Forcing Mycobacterium smegmatis on Alternate Evolutionary Paths.

19. Discovery and characterization of a novel LysinB from F2 sub-cluster mycobacteriophage RitSun.

20. Photoinactivation of Mycobacterium tuberculosis and Mycobacterium smegmatis by Near-Infrared Radiation Using a Trehalose-Conjugated Heptamethine Cyanine.

21. Growing Mycobacterial Biofilm as a Model to Study Antimicrobial Resistance.

22. Detergent-induced quantitatively limited formation of diacyl phosphatidylinositol dimannoside in Mycobacterium smegmatis.

23. Investigation of the antimycobacterial activity of African medicinal plants combined with chemometric analysis to identify potential leads.

24. High-throughput mutagenesis and screening approach for the identification of drug-resistant mutations in the rifampicin resistance-determining region of mycobacteria.

25. Targeted suppression of MEP pathway genes DXS, IspD and IspF to explore the mycobacterial metabolism and survival.

26. A nucleoid-associated protein is involved in the emergence of antibiotic resistance by promoting the frequent exchange of the replicative DNA polymerase in Mycobacterium smegmatis .

27. Targeted protein degradation in mycobacteria uncovers antibacterial effects and potentiates antibiotic efficacy.

28. Lipids Extracted from Mycobacterial Membrane and Enveloped PLGA Nanoparticles for Encapsulating Antibacterial Drugs Elicit Synergistic Antimicrobial Response against Mycobacteria.

29. The Mechanism of Inhibition of Mycobacterial (p)ppGpp Synthetases by a Synthetic Analog of Erogorgiaene.

30. Second messenger c-di-AMP regulates multiple antibiotic sensitivity pathways in Mycobacterium smegmatis by discrete mechanisms.

31. Monitoring Live Mycobacteria in Real-Time Using a Microfluidic Acoustic-Raman Platform.

32. RNA G-quadruplexes inhibit translation of the PE/PPE transcripts in Mycobacterium tuberculosis.

33. GC/MS Profiling and Evaluation of Leaf Essential Oil for Bactericidal Effect and Free Radical Scavenging Activity of Plectranthus amboinicus (Lour.) Spreng Collected from Odisha, India.

34. Inhibition of mycobacteria proliferation in macrophages by low cisplatin concentration through phosphorylated p53-related apoptosis pathway.

35. Molecular dissection of RbpA-mediated regulation of fidaxomicin sensitivity in mycobacteria.

36. Potentiating the Anti-Tuberculosis Efficacy of Peptide Nucleic Acids through Combinations with Permeabilizing Drugs.

37. Kimidinomycin, a new antibiotic against Mycobacterium avium complex, produced by Streptomyces sp. KKTA-0263.

38. Division of labor between SOS and PafBC in mycobacterial DNA repair and mutagenesis.

39. Hydrolyzable tannins (ellagitannins), flavonoids, pentacyclic triterpenes and their glycosides in antimycobacterial extracts of the ethnopharmacologically selected Sudanese medicinal plant Combretum hartmannianum Schweinf.

40. Compensatory effects of M. tuberculosis rpoB mutations outside the rifampicin resistance-determining region.

41. Novel 2,4-disubstituted quinazoline analogs as antibacterial agents with improved cytotoxicity profile: Optimization of the 2,4-substituents.

42. Label-free molecular detection of antibiotic susceptibility for Mycobacterium smegmatis using a low cost electrode format.

43. Structure of the ATP synthase from Mycobacterium smegmatis provides targets for treating tuberculosis.

44. Cell-penetrating peptide conjugates of indole-3-acetic acid-based DNA primase/Gyrase inhibitors as potent anti-tubercular agents against planktonic and biofilm culture of Mycobacterium smegmatis.

45. A synthetic diterpene analogue inhibits mycobacterial persistence and biofilm formation by targeting (p)ppGpp synthetases.

46. DNA binding and gene regulatory functions of MSMEG_2295, a repressor encoded by the dinB2 operon of Mycobacterium smegmatis .

47. Structure of mycobacterial CIII 2 CIV 2 respiratory supercomplex bound to the tuberculosis drug candidate telacebec (Q203).

48. Isolation, characterization of galactose-specific lectin from Odoiporus longicollis and its antibacterial and anticancer activities.

49. Laboratory evolution of Mycobacterium on agar plates for analysis of resistance acquisition and drug sensitivity profiles.

50. A method for the enrichment, isolation and validation of Mycobacterium smegmatis population surviving in the presence of bactericidal concentrations of rifampicin and moxifloxacin.

Catalog

Books, media, physical & digital resources